$SLXN

$0.17 -$0.01 (5.1%) Close

$SLXN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 5.6M shares outstanding

Who owns SLXN?

By type of holder

Institutions 41.9% Insiders 0.0% Everyone else 58.1%

Concentration Top 10 holders own 106.9%

Ilan Levin 35.1% · Moringa Sponsor, LP 35.1%

Institutional ownership

41.9%

-0.9 pts vs last qtr

Institutional holders

-8 vs last qtr

Net shares bought

−47.4K

by institutions in Q2 2026

New / sold out

0 / 8

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Goldman Sachs Group Inc +1.6K

Biggest sellers in Q2 2026

Citadel Advisors LLC SOLD OUT −20.9K
Saba Capital Management, L.P. SOLD OUT −11.9K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Silexion Therapeutics Corp in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2024–FY2025

+3093.3%

+3093.26% a year

Each share's claim on the business

−96.9%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $6M

over 2 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years90% Under 1 year10%

Quarterly turnover

1.1%

of institutional shares changed hands

Top 10 managers, median time held

1.8 years

Super Investors

Investment managers reporting SLXN on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
PA Polar Asset Management Partners Inc.	743.5K	13.37%	Unchanged	2024	0.0%
Shares held by quarter Peak holding743.5K (Q3'24) Change over 8 quarters0 Share of the company13.370% Polar Asset Management Partners Inc.'s full portfolio →
LA Linden Advisors LP	337.5K	6.07%	Unchanged	2024	0.0%
Shares held by quarter Peak holding337.5K (Q3'24) Change over 8 quarters0 Share of the company6.070% Linden Advisors LP's full portfolio →

Polar Asset Management Partners Inc.

743.5K

% of company

13.37%

Change vs last qtr

Unchanged

Held since

2024

Linden Advisors LP

337.5K

% of company

6.07%

Change vs last qtr

Unchanged

Held since

2024

21 more super investors behind a free account

See every manager holding Silexion Therapeutics Corp, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting SLXN on Form N-PORT; together they hold 0.0% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
RC RiverNorth Capital and Income Fund RiverNorth Capital and Income Fund	$405	—	0.00%	0.00%	March 31, 2025
RO RiverNorth Opportunities Fund Inc. Rivernorth Opportunities Fund Inc.	$195	—	0.00%	0.00%	March 31, 2025

RiverNorth Capital and Income Fund

Position value

$405

% of company

0.00%

% of the fund

0.00%

As of

March 31, 2025

RiverNorth Opportunities Fund Inc.

Rivernorth Opportunities Fund Inc.

Position value

$195

% of company

0.00%

% of the fund

0.00%

As of

March 31, 2025

1 more funds behind a free account

See every fund holding Silexion Therapeutics Corp and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
IL Ilan Levin 5%+ holder 13D · 17.7%	2.0M	35.14%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company35.140% Disclosed stake13D · 17.7% View the 13D/G filing →
MS Moringa Sponsor, LP 5%+ holder 13D · 17.7%	2.0M	35.14%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company35.140% Disclosed stake13D · 17.7% View the 13D/G filing →

Ilan Levin

5%+ holder13D · 17.7%

2.0M

% of company

35.14%

Change vs last qtr

—

Held since

—

Moringa Sponsor, LP

5%+ holder13D · 17.7%

2.0M

% of company

35.14%

Change vs last qtr

—

Held since

—

3 more holders behind a free account

See every insider and 5%+ holder of Silexion Therapeutics Corp.

Comments